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Uteroglobin, originally named blastokinin, is a protein syn-
thesized and secreted by most epithelia, including the endo-
metrium. Uteroglobin has strong anti-inflammatory proper-
ties that appear to be due, at least in part, to its inhibitory
effect on the activity of the enzyme phospholipase A2. In
addition, recent experimental evidence indicates that utero-
globin exerts antiproliferative and antimetastatic effects in
different cancer cells via a membrane receptor. The human
endometrial adenocarcinoma cell line HEC-1A does not ex-
press uteroglobin. Thus, we transfected HEC-1A cells with
human uteroglobin cDNA. The transfectants showed a mark-
edly reduced proliferative potential as assessed by impaired
plating efficiency as well as by reduced growth in soft agar.
Cytofluorimetric analysis clearly indicated that in uteroglo-
bin-transfected cells the time for completion of the cell cycle
was increased. We previously demonstrated that HEC-1A
cells actively synthesize platelet-activating factor, one of the
products of phospholipase A2 activity. In addition, we dem-
onstrated that platelet-activating factor stimulates the pro-
liferation of these cells through an autocrine loop. In utero-
globin transfectants, the activity of phospholipase A2 and
platelet-activating factor acetyl-transferase, which are in-
volved in the synthesis of platelet-activating factor, was sig-
nificantly reduced compared with wild-type and vector-trans-
fected cells (p < 0.05). Our results indicate that enforced
expression of uteroglobin in HEC-1A cells markedly reduced
their growth potential and significantly impaired the synthe-
sis of platelet-activating factor, an autocrine growth factor
for these cells. These data suggest that one possible mecha-
nism for the recently observed antineoplastic properties of
uteroglobin may be the inhibition of the synthesis of platelet-
activating factor. Int. J. Cancer 88:525–534, 2000.
© 2000 Wiley-Liss, Inc.
Uteroglobin (UG) (Beier, 1968) or blastokinin (Krishnan and
Daniel, 1967) is a low molecular mass (15.8 kDa) secretory
protein, first discovered in the rabbit uterine fluid during early
pregnancy (see Miele et al., 1994, for review) and subsequently
found in other organs of the female/male genitourinary apparatus,
in the respiratory and gastrointestinal tract and in the blood (Miele
et al., 1994). UG gene expression is under organ-specific hormonal
control. For example, corticosteroids stimulate UG gene expres-
sion in the lung, whereas progesterone exerts an analogous stim-
ulatory effect in the uterus (Miele et al., 1994). Prolactin has been
shown to augment progesterone-dependent UG gene expression
(Kleis-San Francisco et al., 1993). The human counterpart of UG
was first found in nonciliated bronchiolar Clara cells (Plopper et
al., 1980) and was initially named CC10 kDa protein, based on its
apparent molecular weight. Subsequently, it was demonstrated that
the expression pattern (Peri et al., 1993) and the biochemical
properties (Mantile et al., 1993) of CC10 kDa are very similar, if
not identical, to those of rabbit UG, thus reinforcing the hypothesis
that CC10 kDa can be regarded as the human UG. In particular,
Peri et al. (1994) have previously demonstrated that UG mRNA
and protein are readily detectable in the cycling human endome-
trium and that the highest levels of expression are observed in the
lutheal phase of the menstrual cycle.
Several physical and biological properties of UG have been
established. These include binding of progesterone and polychlo-
rinated biphenyls, masking the antigenicity of pre-implantation
embryos and epididymal spermatozoa in vitro, the inhibition of
monocyte and neutrophil chemotaxis and phagocytosis and the
inhibition of ADP- and thrombin-induced platelet aggregation
(Miele et al., 1994). The properties of UG can be due, at least in
part, to its potent inhibitory effect on the activity of low molecular
weight, secretory phospholipases A2 (sPLA2) (Miele et al., 1994).
Two major types of sPLA2, structurally very similar, had been
originally described (see Mukherjee et al., 1992, for review):
sPLA2 type I, found primarily in cobra and sea snake venoms and
in the mammalian pancreas, and type II, found in the venoms of
Crotalidae family of snakes and in the human synovium, neutro-
phils and platelets. Various other mammalian sPLA2s have been
identified that are structurally related to types I and II. At least five
different mammalian sPLA2s have been described (Lambeau and
Lazdunski, 1999). Various unrelated intracellular cPLA2s have
been described (Bingham and Austen, 1999; Mukherjee et al.,
1992). These are thought to participate in receptor-induced arachi-
donic acid (AA) release. Several lines of evidence suggest that
both calcium-dependent and calcium-independent intracellular
PLA2s participate in receptor-induced AA release that is the first
step in eicosanoid metabolism (Xing and Insel, 1996; Hiller and
Sundler, 1999; Akiba et al., 1999; Bingham and Austen, 1999).
This metabolic network is receiving considerable attention as a
potential target for chemopreventive intervention in human malig-
nancies due to the growth-promoting effects of several eicosanoids
(see Marks et al., 1999, for review). In addition, sPLA2s indirectly
induce a variety of autocrine and paracrine effects, including cell
proliferation, AA release and eicosanoid production, through cell
membrane receptors (see Lambeau and Lazdunski, 1999, for re-
view). This implies that sPLA2 receptors can trigger the activation
of intracellular PLA2s (Xing et al., 1995). Conversely, there is
evidence indicating that UG is inversely correlated to neoplastic
growth. UG mRNA is present in normal bronchiolar epithelium,
whereas it becomes undetectable in human lung carcinoma by in
situ hybridization (Broers et al., 1992). Another report confirmed
the markedly less frequent immunohistochemical positivity for UG
in non-small-cell lung carcinoma compared with non-neoplastic
lungs (Linnoila et al., 1992). More recent reports showed that in a
transgenic mouse model for lung carcinoma UG gene expression
was lost with the progression of the tumor to the undifferentiated
phenotype (Sandmoller et al., 1995). Furthermore, UG-knockout
mice have increased incidence of various malignancies (Zhang et
al., 1999). Enforced expression of UG or exogenous treatment
with recombinant UG inhibit anchorage-independent growth and
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matrix invasion in various cancer cell lines (Leyton et al., 1994,
Kundu et al., 1996, 1988; Szabo et al., 1998; Zhang et al., 1999).
Our group has previously demonstrated that in the human en-
dometrial adenocarcinoma cell line HEC-1A platelet-activating
factor (PAF), one of the products of PLA2 activity, is actively
synthesized and stimulates cell proliferation via an autocrine loop
(Maggi et al., 1994). This cell line, in contrast to the normal
endometrium, does not express UG. To investigate the role of UG
as an inhibitor of cell proliferation, we transfected HEC-1A cells
with UG cDNA. Clones expressing UG were selected and the
proliferation rate was assessed using different experimental ap-
proaches. Wild-type HEC-1A cells and mock- (i.e., vector alone)
transfected cells were used as controls. Because of the growth-
promoting effect of PAF in these cells (Maggi et al., 1994), we
investigated whether UG over-expression might affect the path-
ways generating PAF.
MATERIAL AND METHODS
Cell transfection and selection of the clones by RT-PCR
A full-length cDNA coding for human pre-UG was inserted
between the HindIII and the XbaI site in the multiple cloning site
of the expression vector pRc/RSV (Invitrogen, San Diego, CA).
The vector was prepared by Dr. A. Peri and Dr. Z. Zhang in the
Section on Developmental Genetics, Heritable Disorders Branch,
National Institute of Child Health and Human Development, The
National Institutes of Health, Bethesda, MD. This vector contains
a neomycin resistance marker. The vector containing UG cDNA
was linearized and HEC-1A (American Type Culture Collection,
Gaithersburgh, MD) cells were transfected via electroporation and
plated in McCoy’s medium (Sigma, St. Louis, MO) supplemented
with 10% FCS (GIBCO, Grand Island, NY), penicillin (100 units/
ml), streptomycin (0.1 mg/ml), 2.2 g/l sodium bicarbonate and
G418 (Geneticin; Sigma). Forty-four clones were isolated and
expanded. HEC-1A cells were also transfected with solely the
vector (hereafter indicated as mock-transfected cells for conve-
nience) as a control. Sixteen clones were isolated and amplified.
Total RNA was extracted from different clones by using the
RNAzol method (Cinna/Biotecx, Friendswood, TX). Extracted
RNA was subjected to RT-PCR. UG-specific primers and exper-
imental conditions were as described previously (Peri et al., 1993).
After RT-PCR, the amplified products were subjected to agarose
gel electrophoresis, blotted onto nylon membranes and then hy-
bridized to a UG-specific probe, as described previously (Peri et
al., 1993). Out of 44 isolated clones after UG cDNA transfection,
21 showed detectable levels of UG mRNA. Six of the UG-
transfected clones expressing detectable levels of UG and 6 of the
pRc/RSV-transfected clones were selected for subsequent experi-
ments. The quality of the RNAs was assessed by RT-PCR using
primers specific for the housekeeping gene glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (Peri et al., 1993). The experi-
mental conditions for GAPDH RT-PCR were as described previ-
ously (Peri et al., 1993). The amplification process was stopped in
the exponential phase of the reaction. Amplified products were
electrophoresed on agarose gel, blotted onto nylon membranes and
hybridized to a GAPDH-specific probe (Peri et al., 1993).
Western blot analysis for UG detection
The selected clones in which UG mRNA was detectable were
analyzed by Western blot to show the presence of the protein. Cells
grown at confluence were scraped in cold PBS-1 mM EGTA,
centrifuged and the pellets resuspended in lysis buffer (20 mM
Tris, pH 7.4, 150 mM NaCl, 0.25% Nonidet P40, 1 mM Na3VO4,
1 mM PMSF, 1 mM EGTA). Total protein concentrations were
determined, and aliquots containing 40 mg of proteins were diluted
in equal volume of reducing 23 SB (Laemmli’s sample buffer 5
62.5 mM Tris, pH 6.8, containing 10% glycerol, 20% SDS, 2.5%
pyronin and 10% b-mercaptoethanol) with 1 mM EGTA, incu-
bated at 95°C for 5 min and loaded onto 20% polyacrylamide-
bisacrylamide gel. As positive control, 0.5 mg of recombinant
rabbit UG was used. After separation in SDS-PAGE, proteins were
transferred onto nitrocellulose (Sigma) and stained with Ponceau
to verify equal protein loading. The nitrocellulose was blocked in
5% BSA for 2 hr in TTBS solution (Tris-buffered saline containing
0.1% Tween 20, pH 7.4), washed and then immunostained with a
goat anti-rabbit UG antibody (1:100) followed by a peroxidase-
conjugated secondary anti-goat IgG (1:3,000). The anti-rabbit UG
antibody we used specifically recognizes human UG, as assessed
in a previous study (Kikukawa et al., 1988). Reacted bands were
revealed by a chemiluminescent substrate (BM; Roche Diagnos-
tics, Milan, Italy).
Monolayer cloning assay
The method described by Sobrero et al. (1985) was utilized.
Briefly, a monocellular dispersion was obtained by passing the
cells, upon trypsinization, through a 25-gauge needle. The cells
were dispensed at different concentrations into sterile 60 mm Petri
dishes (100-250-500-1,000 cells/well). The number of HEC-1A
cells transfected with UG cDNA was increased (1,000-5,000-
10,000-20,000 cells/well) after the first experiments, since no
colony was observed at the original concentration. The cells were
incubated at 37°C and 100% humidity with 7.5% CO2. Clonal
growth was determined after staining with orcein. Colonies con-
taining more than 200 cells, as assessed by colony dimensions,
were scored at 103 magnification using a dissecting microscope.
Each experimental point was determined in triplicate.
Growth in soft agar
Two percent agar (Fluka, Buchs, Switzerland) was dissolved in
boiling water. After cooling at 80°C, the agar was transferred to a
45°C bath. The agar (2%, 12 ml) was added to the culture medium
(60 ml McCoy’s, supplemented with G418 for the transfected
cells) and was kept at 45°C. The cultured cells were trypsinized to
obtain single-cell suspensions. The cell suspensions were counted
and diluted to give 2,000, 667, 222, 74 cells/ml. Each experimental
point was determined in triplicate. The cells were placed on ice,
then 2.5 ml of the agar-containing medium was mixed with 0.5 ml
cell suspension and poured into a dish immediately. After pouring,
all dishes were placed at 4°C for 10 min, and then incubated in a
humid CO2 incubator. After 15 days, the cell colonies in each dish
were counted.
Cell cycle analysis
Cell cycle studies were performed as previously described (Mu-
ratori et al., 1997). Briefly, HEC-1A cells (wild-type, UG-trans-
fected, mock-transfected) were cultured (approximately 0.7 3 106)
in 100 mm tissue culture plates in 10 ml complete culture medium
for 12 hr, then 5 mg/ml of aphidicolin was added. After 24 hr,
partially synchronized cells (about 80% of total cells) were washed
in PBS and fresh McCoy’s medium was added. At the established
times (every 3 hr for 36 hr), cells were washed twice with cold
PBS without calcium and magnesium, and 1 ml fluorochrome
solution (propidium iodide, 0.05 mg/ml, dissolved in 0.1% sodium
citrate and 0.1% Triton X-100) was added. Each experimental
point was determined in triplicate. Three experiments were per-
formed. Dishes were kept for 60 min in the dark at 4°C and cells
were then detached by scraping and pipetting and transferred to
test tubes for cytofluorimetric analysis. Cell fluorescence was
measured in a FACScan cytometer (Becton Dickinson, Mountain
View, CA). The LYSYS II software was used to determine the
distribution of cells in the various cell cycle stages as G0/G1, S
and G2.
Binding studies
Binding experiments were performed as previously described
(Maggi et al., 1994). HEC-1A cells (wild-type and UG-trans-
fected) grown to confluence in 24-well plastic plates were incu-
bated at 4°C for 24 hr in the presence of a fixed concentration (2
nM) of [3H]PAF with increasing concentration (0.3–100,000 nM)
of unlabeled PAF. All the measurements were obtained in tripli-
cate. At the end of the incubation time, the supernatants were
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removed, the cells were washed 6 times in ice-cold Dulbecco-
modified PBS containing 3 mg/ml BSA and then solubilized in 200
ml of 1% SDS containing 0.25 N NaOH. In a beta counter, 190 ml
of the total volume was counted.
Mitogenic assay ([3H]thymidine incorporation)
Experimental conditions were as previously described (Maggi et
al., 1994). Briefly, cells were plated in 24-well plastic plates. After
2 days of culture, cells were maintained for 24 hr in serum-free
medium, and PAF (3 or 10 mM) or vehicles were added. All
treatments were performed in triplicate. The cells were then incu-
bated for 24 hr, and [3H]thymidine (1 mCi/well) was added during
the last 4 hr. Cells were washed twice with ice-cold 5% trichlo-
roacetic acid and solubilized with 0.25 N NaOH in 0.1% SDS at
37°C for 20 min. Aliquots were transferred to plastic vials and
counted by liquid scintillation.
[3H]AA release
These experiments were performed as previously described
(Baldi et al., 1993). Briefly, cells were grown to confluence on
6-well plastic plates, washed twice in serum-free McCoy’s 5A
medium containing 0.1% BSA and pre-incubated in the same
buffer in the presence of [3H]AA (2 mCi/ml) overnight. Each
experimental point was determined in triplicate. The reaction was
stopped by placing tubes on ice. Supernatants were collected and
lipids extracted according to Bligh and Dyer (1959). The chloro-
form phase was dried under nitrogen, reconstituted in chloroform/
methanol (9:1) and applied to silica gel t.l.c. plates. The solvent
system used was hexane/ethyl ether/acetic acid (70:30:1). [3H]AA
was identified by co-chromatography with a known standard and
visualized under a UV lamp after exposure to fluorescein. Areas
corresponding to AA were scraped and counted by liquid scintil-
lation.
Lyso-PAF:acetyl-CoA acetyl-transferase activity
PAF acetyl-transferase activity was determined in cell lysates by
the incorporation of [3H]acetyl from radiolabeled acetyl-CoA into
[3H]PAF, using lyso-PAF as substrate, as described previously
(Villani et al., 1991). Cells were sonicated in a buffer containing
0.1 M Tris-HCl (pH 7), 5 mM dithiothreitol, 0.5 mM EGTA. The
homogenate was resuspended in the same buffer containing 1 mM
CaCl2 and centrifuged at 500 g for 5 min at 4°C. Aliquots of
supernatant were incubated for 5 min at 37°C in a shaking water-
bath in the presence of 30 mM lyso-PAF. [3H]acetyl-CoA (5 mCi)
was then added and incubation proceeded for 15 min. The reaction
was stopped by addition of chloroform/methanol/acetic acid (1:2:
0.04); lipids were extracted and PAF separated by t.l.c. as de-
scribed above. All the measurements were obtained in triplicate.
Statistical analysis
Binding data were evaluated quantitatively with non-linear least-
squares curve fitting using the computer program LIGAND (Munson
and Rodbard, 1980), as previously described (Maggi et al., 1994). The
program provides objective measures of goodness-of-fit and objective
criteria for distinguishing between models of different complexity.
The selection of the best model was based on comparison of the
weighted sum of squares and/or the root mean square error. An F-test
based on the “extra sum of squares” principle was used. Results were
expressed as mean 6 SE or SD. Statistical comparisons were per-
formed using unpaired Student’s t-test.
RESULTS
Selection of transfected cell clones expressing UG
After transfection of HEC-1A cells with human UG cDNA, cell
clones were tested for the presence of UG mRNA and protein. UG
mRNA was assayed by RT-PCR. The expected 278 bp signal was
detected by agarose gel electrophoresis of the RT-PCR products
from 21 UG-transfected clones (not shown). The specificity of the
signal was assessed by Southern blotting, using a UG-specific
oligonucleotide as the probe. In Figure 1, the hybridization pattern
of two (#4 and #7) of the clones exhibiting detectable levels of UG
mRNA is shown. Neither HEC-1A wild-type cells nor mock-
transfected cells (16 isolated clones) exhibited any positivity for
UG mRNA (Fig. 1). Compared with the previously reported phys-
iological expression of UG in the human endometrium (Peri et al.,
1994), UG mRNA levels in UG-transfected cells appeared similar
in most cases and lower in some of the examined clones. There-
fore, the observed effects of UG transfection on HEC-1A cells are
unlikely to be due to over-expression of UG above the physiolog-
ical range. The good quality of the RNAs used in these experi-
ments was verified by RT-PCR, using a pair of primers specific for
the housekeeping gene glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH). GAPDH mRNA levels were virtually the same in
all the samples examined (not shown). In Western blot experi-
ments, UG was detected in HEC-1A cells transfected with UG
cDNA and exhibiting detectable levels of UG mRNA, whereas
neither mock-transfected nor wild-type cells showed any positivity
(Fig. 2). Interestingly, no signal corresponding to UG monomer
(around 5 kDa) was apparently detected, as expected under reduc-
ing conditions (see Material and Methods). However, the higher
molecular weight signals observed in UG-transfected cells could
be representative of enzymatic modifications of UG monomers.
UG is a substrate for transglutaminase (Manjunath et al., 1984),
and this enzyme can crosslink UG monomers to amines altering its
electrophoretic mobility (Porta et al., 1990). Virtually identical UG
migration patterns have been observed by our group in different
cell lysates (i.e., spermatozoa and lymphocytes; unpublished data).
Effect of UG transfection on cell proliferation
Six of the UG-transfected clones, exhibiting detectable levels of
UG, and 6 of the mock-transfected clones were used for the
experimental work reported in this study. Two different ap-
proaches (monolayer cloning assay and growth in soft agar) were
used to determine the effects of UG expression on cell prolifera-
tion. In the first approach, the cells were plated at different con-
centrations on solid supports (Petri dishes). The plating efficiency
of UG-transfected, mock-transfected and wild-type HEC-1A cells
is reported in Figure 3. The data show that transfection with UG
cDNA severely impairs cell proliferation. The plating efficiencies
of the different cell subtypes, calculated according to Sobrero et al.
(1985) was 33 6 4% (mean 6 SD, n 5 6, the mean value is
inclusive of all the different cell concentrations plated) for
HEC-1A wild-type cells, 25.66 6 2.61% (n 5 2) for mock-
transfected cells and 1.17 6 0.68% (n 5 4) for UG-transfected
cells. Using a different experimental design, HEC-1A wild-type
and UG-transfected cells were plated at different concentrations
(2,000/ml, 667/ml, 222/ml and 74/ml) and grown in soft agar.
Anchorage-independent growth, as occurs in soft agar, is a feature
FIGURE 1 – Chemilumigram showing RT-PCR products from total
RNAs using UG-specific primers, after hybridization with a UG-
specific oligonucleotide probe. St, DNA molecular weight marker
standard VI-digoxigenin labeled (Roche Diagnostics, Milan, Italy); N,
no RNA control reaction; WT, wild-type HEC-1A cells; MOCK, one
clone of HEC-1A cells transfected with pRc/RSV vector; #4 and #7,
different HEC-1A UG-transfected clones, expressing UG.
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of neoplastic cells. Wild-type HEC-1A cells formed large colonies
in these conditions (Fig. 4a). The number of colonies ranged from
45 at the highest plating concentration to 3 at the lowest concen-
tration. Conversely, UG-transfected cells appeared only as spread
cells (Fig. 4b) and formed only a single colony at the highest
plating concentration (not shown).
Cell cycle analysis
To determine the effect of UG transfection on cell cycle pro-
gression, flow cytometric analysis of DNA content in cells
(HEC-1A wild-type, mock-transfected and UG-transfected) syn-
chronized with aphidicolin was performed. Figure 5 shows the
results of a typical experiment. After 24 hr exposure to 5 mg/ml
aphidicolin, a potent nonspecific inhibitor of DNA polymerase a,
about 80% of the cells in the 3 groups were in Go/G1-early S, as
indicated by fluorescence emission of propidium iodide-stained
nuclei of the cells (Fig. 5, top row). After removal of aphidicolin,
wild-type and mock-transfected cells showed a faster progression
through the cell cycle than UG-transfected cells, entering S and
G2/M at earlier times. Six hours after aphidicolin release, 73% of
wild-type and 67% of mock-transfected cells were traversing S,
whereas only 58% of UG-transfected cells were in S (Fig. 5,
second row from the top). After a 12 hr release from aphidicolin
block, 70% of wild-type and 54% of mock-transfected cells were
in G2/M (Fig. 5, third row). Forty-nine percent of UG-transfected
cells were still traversing S and only 38% were in G2/M. Six hours
later, 41% of wild-type and 36% of mock-transfected cells were
back in Go/G1 compared with only 14% of UG-transfected cells(Fig. 5, fourth row). Twenty-four hours after aphidicolin release,
about 60% of the wild-type and mock-transfected cells were re-
plenishing Go/G1 (45% of both cell subtypes) or were traversing S(15% and 18%, respectively) (Fig. 5, fifth row). Conversely, most
of UG-transfected cells were still in G2/M (68%) and only 23%
were back in Go/G1. Only 12 hr later, UG-transfected cells par-
tially accumulated in Go/G1 (46%; Fig. 5, lowest row), whereas a
reduction in the amount of wild-type and mock-transfected cells in
Go/G1 was observed compared with the previous experimental
point shown in the figure (40% and 38%, respectively), concom-
itantly to an increased number of cells traversing S (19% and 31%,
respectively).
PAF-mediated loop
Because UG-transfected cells exhibited a lower proliferative
activity than mock-transfected and nontransfected controls, we
speculated that UG expression may affect the expression or the
downstream signaling of molecules acting as growth factors for
these cells. We therefore investigated whether or not UG expres-
sion interferes with the autocrine proliferative loop mediated by
PAF, a phospholipid growth factor for HEC-1A cells. First, we
studied the effect of UG transfection on the density and affinity of
PAF receptors. Binding studies were performed as described
(Maggi et al., 1994). Figure 6 shows the results of a typical PAF
binding experiment performed simultaneously in wild-type and
UG-transfected HEC-1A cells. Mathematical analysis of binding
data using the program LIGAND (Munson and Rodbard, 1980)
indicated that the two displacement curves were virtually identical.
The curves share the same binding parameters (high-affinity site
Bmax 5 31.41 6 11.62 fmol/106 cells and Kd 5 0.3 6 0.16 nM;
low-affinity site Bmax 5 16.46 6 14.59 nmol/106 cells and Kd 5
0.66 6 0.40 mM). These data indicate that UG transfection does
not affect the expression of PAF receptors. To verify whether or
not UG transfection interferes with PAF responsiveness, we stim-
ulated wild-type, mock-transfected and UG-transfected HEC-1A
cells with PAF and studied the effect of PAF on DNA synthesis.
The results are shown in Table I, expressed as percentage [3H]thy-
midine uptake vs. control, i.e., untreated cells. In each of the 3
subgroups, a 24 hr incubation with PAF, added to the cultured cells
at 2 different concentrations (3 and 10 mM), induced a statistically
significant increase of [3H]thymidine incorporation (p , 0.05)
compared with controls. The mean of the control values in each
subgroup was given an arbitrary value of 100. However, we found
no differences in the ability of the 3 distinct subgroups to respond
to PAF. This confirms that UG transfection does not affect the
capability of HEC-1A cells to respond to PAF.
We therefore sought to determine whether the activity of 2 key
enzymes in the synthesis of PAF, namely PLA2 and PAF acetyl-
transferase, was reduced in UG-transfected cells. We determined
PLA2 activity in cultured cells by measuring AA release. The
results, reported in Figure 7, indicated that the release of AA in
HEC-1A cells and in mock-transfected cells is not statistically
FIGURE 2 – Western blot analysis of UG content. The numbers on
the right indicate the molecular weight (kDa) of the bands of the
molecular weight marker. UG, HEC-1A clone transfected with UG
cDNA; MOCK, HEC-1A clone transfected with pRc/RSV vector; WT,
wild-type HEC-1A cells; rUG, recombinant rabbit uteroglobin; MW,
molecular weight marker.
FIGURE 3 – Plating efficiency of HEC-1A wild-type (WT), mock-
transfected (MOCK) and UG-transfected cells (UG) as determined by
the method described by Sobrero et al. (1985). The numbers express
the percentage of the cell colonies containing more than 200 cells.
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different, whereas a statistically significant lower value was ob-
tained in UG-transfected cells compared with the 2 other groups of
cells (p , 0.05). Furthermore, the activity of PAF acetyl-trans-
ferase was determined in wild-type as well as in UG- and mock-
transfected HEC-1A cells. The experimental results are shown in
Figure 8. As expected, PAF acetyl-transferase activity did not
FIGURE 4 – Cell growth in soft agar. (a) HEC-1A wild-type cells were able to form colonies in these conditions; (b) HEC-1A cells transfected
with UG cDNA did not retain this characteristic and only single spread cells were observed. Scale bar 5 10 mm.
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significantly differ (p 5 0.13) in wild-type and mock-transfected
cells. Conversely, a significant reduction in enzymatic activity was
observed in UG-transfected cells compared with wild-type and
mock-transfected cells (p , 0.05).
DISCUSSION
In this study, we demonstrated that UG inhibits the proliferation
and cell cycle progression of neoplastic cells from the human
endometrium and that this effect appears to be mediated by a
FIGURE 5 – Flow cytometric analysis of cell cycle distribution of synchronized HEC-1A wild-type cells (WT), UG-transfected (UG) and
mock-transfected (MOCK) cells 0, 6, 12, 18, 24 and 36 hr after release from aphidicolin block.
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disruption in the metabolic pathways generating PAF. In a previ-
ous study investigating for the first time UG expression in human
organs, Peri et al. (1993) found that UG is expressed in a number
of human tissues and that epithelial cells are the primary site of UG
synthesis. Subsequently, we demonstrated that UG expression in
the endometrium is dependent on the hormonal environment of sex
steroids. In particular, the levels of UG mRNA and protein were
shown to peak in the secretory phase of the ovarian menstrual
cycle (Peri et al., 1994). However, when we investigated UG
expression in a human endometrial cancer cell line, HEC-1A, no
detectable amounts of either mRNA or protein were found.
In view of this discrepancy between normal and neoplastic endo-
metrium, we investigated a possible relationship between UG and
endometrial cancer. The first step was to stably transfect HEC-1A
cells with an expression vector containing UG cDNA. The obtained
cell clones were selected on the basis of the presence of UG transcript
and protein. Subsequently, 6 of the clones expressing UG were
subjected to studies assessing their neoplastic phenotype compared
with wild-type cells. Mock-transfected cells (transfected with the
vector in the absence of UG cDNA) were generated and used as
controls in our experiments to rule out nonspecific effects due to the
expression vector or the manipulations associated with cell transfec-
tion and selection. UG-transfected cells unequivocally exhibited
markedly reduced proliferation rate and impaired anchorage-indepen-
dent growth compared with wild-type and mock-transfected cells.
High plating efficiency (clonogenicity) and anchorage-independent
growth are important phenotypic parameters that characterize trans-
formed cells. Flow cytometric analysis of aphidicolin-synchronized
cells indicated that in UG transfectants cell cycle progression is
markedly slowed compared with wild-type and mock-transfected
HEC-1A cells. This effect appeared to be equally distributed among
the different phases of the cell cycle rather than being the result of
arrest at a single cell cycle checkpoint.
In principle, a tumor suppressor-like effect of UG is not sur-
prising. In fact, the UG gene maps to chromosome 11q12.2–13.1
(Zhang et al., 1997a). Rearrangements or deletions of this region
of chromosome 11 have long been known to be associated with
human malignancies (Misra and Srivastan, 1989; Lammie et al.,
1991; Jesudasan et al., 1995). In addition, it has been reported that
the introduction of chromosome 11 into cervical cancer cells
(HeLa) suppresses the neoplastic phenotype of these cells (Saxon
FIGURE 6 – Displacement curve for PAF binding to wild type (n )
and UG-transfected (h) HEC-1A cells. Ordinate, B/T; abscissa, total
ligand concentration (labeled and unlabeled) (T) on log scale.
TABLE I – EFFECTS OF 2 DIFFERENT CONCENTRATIONS OF PAF ON
[3H]THYMIDINE UPTAKE IN WILD-TYPE (WT), MOCK-TRANSFECTED
(MOCK) AND UG-TRANSFECTED (UG) HEC-1A CELLS
PAF [M] HEC-1A WT HEC-1A MOCK HEC-1A UG
3E-6 148.33 6 6.74 153.33 6 8 154 6 12.5
1E-5 167 6 5.68 147.66 6 9.33 160.33 6 12.66
Values (mean 6 SE, n 5 3) are expressed as percentage of control
(100%). The differences among all pairs at the same concentration of
PAF were not statistically significant (p $ 0.05).
FIGURE 7 – Arachidonic acid release in wild-type (WT), mock-
transfected (MOCK) and UG-transfected (UG) HEC-1A cells. n, num-
ber of experiments. The value representing the mean among the
experimental determinations (in triplicate in 3 different experiments)
for WT cells was considered as 1. The determinations (mean 6 SE) for
MOCK and UG cells are expressed as fold increase vs. WT. *,
statistically significant at the 0.05 level.
FIGURE 8 – Acetyl-transferase activity in wild-type (WT), mock-
transfected (MOCK) and UG-transfected (UG) HEC-1A cells. n, num-
ber of experiments. The values (mean 6 SE) are expressed in cpm/
mg/min, where mg indicates mg of protein. *, statistically significant at
the 0.05 level.
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et al., 1986). Recombinant human UG inhibits the in vitro inva-
siveness of human metastatic prostate cancer cells (Leyton et al.,
1994). Furthermore, Szabo et al. (1998) over-expressed UG in the
non-small-cell lung cancer (NSCLC) cell line A549; this cell line,
like most NSCLC lines, does not express UG. A549 cells, upon
transfection with UG, showed a marked reduction in invasiveness
that was paralleled by diminished metalloproteinase activity and
by decreased anchorage-independent growth. In addition, the UG
transfectants exhibited decreased adhesion to fibronectin. The au-
thors hypothesize that since the binding of fibronectin to its inte-
grin receptors initiates a cascade leading to stimulation of growth
or suppression of apoptosis, the interruption of such a signal
cascade by UG may be responsible, at least in part, for its anti-
neoplastic activity. A severe renal glomerular disease associated
with massive glomerular deposition of fibronectin has been ob-
served in mice in which the UG gene had been disrupted (Zhang
et al., 1997b). The molecular mechanism that normally prevents
fibronectin deposition appears to involve high-affinity binding of
UG with fibronectin to form heterodimers that counteract fibronec-
tin self-aggregation. Most interestingly, preliminary results of ag-
ing studies on UG-knockout mice revealed a high incidence of
malignancies (UG-knockout mice, 16/16 vs. wild-type littermates,
0/25) (Zhang et al., 1999).
The mechanism(s) of the apparent tumor suppressor-like effects
of UG require further investigation. Our data suggest that one of
these mechanisms may involve the inhibition of AA release and of
the synthesis of lipid growth factors such as PAF. It is unclear
which PLA2(s) participate in AA release in HEC-1A cells. The
inhibition of AA release by UG in this system may be due to direct
inhibition of one or more mammalian sPLA2(s) and/or to effects
mediated by the UG receptor (Kundu et al., 1996, 1998), to
inhibition of integrin-fibronectin binding (see above) or to hitherto
unrecognized mechanisms. UG has been demonstrated to be a very
strong inhibitor of sPLA2 activity, and this effect appears to be due
to direct interaction between UG and sPLA2 with interference with
the process of interfacial activation (Miele et al., 1994). A direct
inhibition of sPLA2 in a system in which such enzymes release AA
from intact membranes could in principle result in decreased
production of growth-promoting eicosanoids and PAF. On the
other hand, sPLA2s also stimulate AA release (Xing et al., 1995),
prostaglandin synthesis (Kishino et al., 1995), cell growth (Arita et
al., 1991) and extracellular matrix invasion (Kundu et al., 1997)
through receptor-mediated mechanisms that do not require their
catalytic activity (see Lambeau and Lazdunski, 1999, for review).
UG is structurally similar to sPLA2s (Mukherjee et al., 1992), and
it is an intriguing possibility that UG may function as an antagonist
to receptor-mediated sPLA2 effects, either by directly binding to
sPLA2 or to the sPLA2 receptor or indirectly through its own
receptor. Finally, inhibition of integrin-fibronectin binding could
in principle lead to reduced AA release by preventing the activa-
tion of intracellular PLA2(s) via protein kinase C or MAP kinases.
PAF is an acetylated alkyl ether glycerophospholipid produced
by a variety of cell types and tissues, including inflammatory cells,
epithelial cells, neurons, heart, lung, liver, kidney and exocrine
glands (Bussolino and Camussi, 1995). After synthesis, PAF may
either be released in extracellular fluids or remain exposed on the
outer plasma membrane (Bussolino and Camussi, 1995). The
synthesis of PAF from its precursor lyso-PAF depends on an
acetyl-transferase reaction. The pathway by which PAF is gener-
ated through a tightly coupled reaction of PLA2 and an acetyl-
transferase is indicated as the remodeling pathway (Bussolino and
Camussi, 1995). Alternatively, PAF synthesis occurs also by a
different route, named the de novo pathway, through the activity of
the enzyme cholinephosphotransferase on the substrate 1-alkyl-2-
acetyl-sn-glycerol (Bussolino and Camussi, 1995). Both enzymatic
activities occur at relatively high levels in most cells.
We previously reported that HEC-1A cells synthesize PAF and
respond to it via specific cell membrane receptors (Maggi et al.,
1994). PAF binding to HEC-1A cells induced DNA synthesis, ex-
pression of the nuclear proto-oncogene c-fos and calcium influx
(Maggi et al., 1994). In addition, other reports indicated that PAF
increases tyrosine kinase activity both in platelets (Danhauser-Riedl et
al., 1991) and in proliferating cells (Chao et al., 1992; Tripathi et al.,
1992). Recently, our group demonstrated that the mitogenic effect of
PAF in HEC-1A cells is mediated by the activation of multiple
signaling pathways, involving protein tyrosine kinase, mitogen-acti-
vated protein kinase and protein kinase C (Bonaccorsi et al., 1997).
It should be noted that Camussi et al. (1990) have shown that
synthetic oligopeptides derived from the putative active site of UG,
named antiflammins (see Miele, 2000, for review), have essentially
the same effects on human neutrophils as we have seen in HEC-1A
cells with UG expression. These authors have shown that antiflam-
mins inhibit AA release, the activation but not the catalytic activity
of human neutrophil PLA2 and the activity of lyso-PAF acetyl-
transferase. Our results indicated that AA release and acetyltrans-
ferase activity were reduced in UG transfectants compared with
wild-type and mock-transfected cells. These findings suggest the
possibility that the antiproliferative effects of UG in HEC-1A cells
may be in part correlated to suppression of the enzymatic activities
ultimately leading to the synthesis of PAF. The molecular mech-
anism(s) responsible for these effects of UG and antiflammins will
require further investigation. However, our results suggest that the
inhibition of PAF synthesis may be a common mechanism that
contributes to the anti-inflammatory and antineoplastic properties
of UG. The possible role of the sPLA2 receptors and/or the UG
receptors deserves careful consideration in light of the receptor-
mediated effects of sPLA2s on growth and invasion (see above)
and of the fact that the antichemoinvasive effects of UG appear to
require the presence of UG receptors (Zhang et al., 1999).
In conclusion, in this study we have addressed the potential role
of UG as a secretory tumor-suppressor protein in human endome-
trial carcinoma cells. We have demonstrated that UG expression
significantly affects cell cycle progression and anchorage-indepen-
dent growth and inhibits AA release and PAF synthesis. The latter
effect may be responsible for its antiproliferative effect in this
experimental model.
Together with reports from other groups (Broers et al., 1992;
Linnoila et al., 1992; Leyton et al., 1994; Sandmoller et al., 1995;
Nord et al., 1998; Szabo et al., 1998; Zhang et al., 1999), this study
suggests that loss of UG expression may potentially be a diagnos-
tic/prognostic marker in some human malignancies and that UG
itself, administered as a recombinant protein or through gene
therapy strategies, may have significant antineoplastic activity.
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